Technologies related to Therapeutic (small molecule)

Title
Potential Treatment for sickle-cell disease and thalassemia
Ref: E-200-2018-0 | Updated: Jan 17, 2019
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
Ref: E-161-2014-0 | Updated: Aug 24, 2018
Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies
Ref: E-263-2013-0 | Updated: Jul 16, 2018
Novel Peptide of Streptococcus pneumoniae Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development
Ref: E-338-2013-0 | Updated: Jun 13, 2018
Potential New Drugs for Treating or Preventing Pruritus
Ref: E-485-2013-1 | Updated: Jun 7, 2018
Methods of Making and Using Dopamine D3 Receptor Selective Antagonists/Partial Agonists
Ref: E-053-2016/0 | Updated: Mar 8, 2017
Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists
Ref: E-213-2015-0 | Updated: Sep 6, 2016
Long Acting Therapeutic Conjugates with Evans Blue
Ref: E-143-2015/0 | Updated: Jun 27, 2016
Thalidomide Analogs that Inhibit Inflammation and Angiogenesis
Ref: E-208-2015-0 | Updated: Jan 4, 2016
Mice with a Floxed Allele of the alpha Subunit of the Heterotrimeric G Protein Go or Gi2
Ref: E-071-2014-0 | Updated: May 14, 2018
TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes
Ref: E-071-2014-2 | Updated: May 14, 2018
Mouse Model for Study of Diabetic Nephropathy and Role of Soluble Epoxide Hydrolase
Ref: E-292-2015-0 | Updated: May 24, 2016
Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2
Ref: E-141-2015/0 | Updated: Aug 10, 2015
Novel Dopamine D2 Receptor Antagonists and Methods of Their Use
Ref: E-030-2013/0 | Updated: Sep 5, 2017
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Ref: E-070-2014/0 | Updated: Mar 22, 2016
Cannabinoid Receptor Meditating Compounds for Metabolic Disease
Ref: E-140-2014/0 | Updated: Aug 23, 2017
Use of Small Molecules to Treat PARP1-deficient Cancers
Ref: E-039-2014/0 | Updated: Dec 16, 2015
MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies
Ref: E-185-2013/0 | Updated: May 15, 2014
Role of Novel Hepatitis Delta Virus Variant in Sjogren’s Syndrome
Ref: E-736-2013-0 | Updated: Apr 14, 2014
Novel Small Molecule Antimalarials for Elimination of Malaria Transmission
Ref: E-751-2013/0 | Updated: Nov 18, 2015
Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells
Ref: E-342-2013-0 | Updated: May 14, 2018
Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response
Ref: E-236-2013/0 | Updated: Feb 19, 2014
Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein
Ref: E-067-2012/0 | Updated: Apr 15, 2014
Therapeutic, Bifunctional Janus Microparticles with Spatially Segregated Surface Proteins and Methods of Production
Ref: E-457-2013/1 | Updated: Jan 28, 2014
Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin
Ref: E-196-2013/0 | Updated: Mar 3, 2017
Methods of Treating or Preventing Pruritis (Itch)
Ref: E-485-2013 | Updated: May 31, 2018
Methods of Treating or Preventing Pruritis (Itch)
Ref: E-485-2013-0 | Updated: Jun 7, 2018
Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics
Ref: E-210-2013/0 | Updated: Mar 3, 2017
Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics
Ref: E-308-2013-0 | Updated: Jun 14, 2018
Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics
Ref: E-258-2013-0 | Updated: Dec 4, 2013
Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies
Ref: E-144-2012-0 | Updated: May 1, 2018
Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases
Ref: E-080-2012-0 | Updated: Sep 17, 2019
Lenalidomide Analogs for the Treatment of Neurodegenerative Disorders and Cancer
Ref: E-045-2012/0 | Updated: Dec 14, 2017
Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutic Agents
Ref: E-116-2004/0 | Updated: Jun 29, 2017
Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease
Ref: E-130-2004-0 | Updated: May 4, 2018
Subscribe to Technologies related to Therapeutic (small molecule)